- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05629689
Um estudo para avaliar a segurança e a tolerabilidade do GEH200520/GEH200521 (18F) quando usado para exames de PET em pacientes com tumores malignos sólidos
Um estudo de fase 1a/1b, multicêntrico, aberto, escalonamento de dose e expansão de dose em pacientes com tumores malignos sólidos para avaliar a segurança e tolerabilidade da injeção GEH200520 / GEH200521 (18F), imagem PET, farmacocinética e alterações na Imagem após o tratamento
Part A: The purpose of this part is to assess the safety of GEH200520 and GEH200521 (18F) when administered to patients with solid cancer. Subjects will be requested to complete 3 study visits: 1 screening visit, 1 imaging visit (over 24 hours) and 1 follow-up visit (7 days later). The estimated duration of Part A is 21 days.
Part B: The purpose of this part of the study is to assess the imaging quality and findings as well as the safety and tolerability of GEH200520 and GEH200521 (18F) when administered to patients with cancer before and after immunotherapy treatment.
Subjects will be requested to complete 7 study visits: 1 screening visit, the first imaging visit, followed by 2 immunotherapy immune-checkpoint inhibitor (ICI) treatment visits and 2 additional imaging and 1 follow-up visit. Two late imaging transfer expected post follow up visit. The estimated duration for subject participation in Part B is approximately 64 days.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Amsterdam, Holanda
- Amsterdam UMC
-
Groningen, Holanda
- UMC Groningen
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- The subject is able and willing to comply with all study procedures as described in the protocol, including the imaging day pre-visit requirements, and has read, signed, and dated an informed consent form prior to any study procedures being performed.
- The subject is male or female, ≥18 years of age.
- Subject has a life expectancy ≥12 weeks.
- Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Subject has an unresectable or metastatic solid tumour or a local and resectable head and neck squamous cell carcinoma, or an unresectable stage III-IV melanoma.
- Subject is eligible for ICI treatment per Investigator judgement.
- Subject has at least 1 measurable tumour lesion documented on CT/magnetic resonance imaging (MRI) RECIST v1.1 during the last 12 months.
- Subject has a tumour lesion(s) of which a biopsy can safely be obtained according to standard clinical care procedures.
- Subject is male or female that agrees to adhere to the protocol contraception methods.
Exclusion Criteria:
- Subject is unable to undergo all procedures in the study and/or is unable to remain still and tolerate the imaging procedure.
- Subject has 12-lead ECG significant findings during screening, per Investigator's assessment.
- Subject is not stable due to medical condition or therapy that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents.
- Subject has serious non-malignant disease or conditions that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has B or T cell lymphoma.
- Subject has brain or bone-marrow metastasis that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has signs or symptoms of systemic infection within 2 weeks prior to imaging day.
- Subject has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins or known allergy to the study IMP ingredients and/or the proposed ICI therapy.
- Subject has any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the ICI treatment, or that may affect the interpretation of the results or render the subject at high risk from complications.
- Subject has laboratory values out of range per protocol.
- Subject has any safety laboratory test results (blood chemistry, haematology, and urinalysis) that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has had any major surgery within 4 weeks prior to enrollment.
- Subject has been enrolled in another interventional clinical study within the 30 days before screening for this study, except for the study site IIS.
- Subject is pregnant or planning to become pregnant or is breastfeeding.
- Subject has a history of alcohol or drug abuse within the last year.
- Subject has had treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to dosing with the IMP.
- Subject has had treatment with systemic immunosuppressive medications within 2 weeks prior to dosing with the IMP.
- Subject has received acute, low-dose, systemic immunosuppressant medications that, in the opinion of the Investigator, could compromise protocol objectives.
- Subject has used systemic corticosteroids to treat inflammatory or autoimmune symptoms.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part A Cohort 1 - 1 mg dose
1 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Experimental: Part A Cohort 2 - 2 mg dose
2 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Experimental: Part A Cohort 3 - 4 mg dose
4 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Experimental: Part A Cohort 4 - 8 mg dose
8 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Experimental: Part A Cohort 5 (optional) - 12 or 15 mg dose
12 or 15 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Experimental: Part A Cohort 6 - Optimal dose
Selected (optimal) mass dose as determined from results of Cohorts 1 through 5 of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Experimental: Part B
Selected (optimal) dose of GEH200520 Injection from Part A with fixed dose of GEH200521 (18F) Injection administered together in 3 sequential repeat imaging visits |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Parte A: A incidência de EAs na causalidade aos IMPs.
Prazo: Parte A: 7 dias
|
Parte A: 7 dias
|
|
Parte A: A gravidade dos EAs de acordo com os Critérios Comuns de Terminologia do National Cancer Institute para Eventos Adversos (NCI CTCAE versão 5.0) sobre causalidade para os IMPs.
Prazo: Parte A: 7 dias
|
Parte A: 7 dias
|
|
Avaliar as alterações ao longo do tempo na captação de injeção de GEH200521 (18F) após ciclos de tratamento com inibidor de ponto de verificação imunológico (ICI) em comparação com a linha de base.
Prazo: Parte B: 50 dias
|
Parte B: 50 dias
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Avaliar a dosimetria de radiação de uma dose fixa de injeção de GEH200521 (18F) quando administrada com as diferentes doses de massa de injeção de GEH200520 por atividade acumulada em regiões de origem e por todo o corpo.
Prazo: 7 dias
|
7 dias
|
|
|
Avaliar a janela de tempo de imagem ideal para imagens de tomografia por emissão de pósitrons (PET) GEH200521 (18F) quando administradas com diferentes doses em massa de injeção GEH200520 para indivíduos da Parte A.
Prazo: 7 dias
|
7 dias
|
|
|
Determinar a dose em massa apropriada de GEH200520 Injection para administração com GEH200521 (18F) Injection para obter uma qualidade de imagem PET aceitável para indivíduos da Parte A.
Prazo: 7 dias
|
7 dias
|
|
|
Avaliar a imunogenicidade, por meio da incidência de respostas de anticorpos antidroga induzidas pelo tratamento, após uma única injeção das diferentes doses em massa de GEH200520 Injection administradas com uma dose fixa de GEH200521 (18F) Injection para indivíduos da Parte A.
Prazo: 7 dias
|
7 dias
|
|
|
Coleta da incidência, gravidade, mudanças entre as visitas para EAs/SAEs/AESIs
Prazo: 50 dias
|
50 dias
|
|
|
Avaliar a biodistribuição e a captação tumoral da injeção de GEH200521 (18F) com a dose ideal de injeção de GEH200520 determinada na Parte A com base em medições quantitativas de GEH200521 (18F) em regiões de interesse para os indivíduos da Parte B.
Prazo: 50 dias
|
50 dias
|
|
|
Avaliar a relação entre a absorção de injeção de GEH200521 (18F) do tumor (valor SUV) e a pontuação de expressão de células imunes CD8+ de uma amostra de biópsia/lesão ressecada, quando disponível, com base nos resultados de IHC para indivíduos da Parte B.
Prazo: 50 dias
|
50 dias
|
|
|
Para comparar as alterações na absorção de injeção do tumor GEH200521 (18F) com as alterações na avaliação da imagem da tomografia computadorizada (TC), de acordo com os Critérios de Avaliação de Resposta em Tumores Sólidos (RECIST) v1.1 para indivíduos da Parte B, quando disponível.
Prazo: 50 dias
|
50 dias
|
|
|
Para comparar as alterações na absorção de injeção de GEH200521 (18F) do tumor com alterações na avaliação da imagem da tomografia computadorizada (TC), de acordo com varreduras de [18F]-fluorodesoxiglicose (FDG), quando disponível para indivíduos da Parte B.
Prazo: 50 dias
|
50 dias
|
|
|
Comparar a imunogenicidade, por meio da incidência de respostas de anticorpos antidrogas induzidas pelo tratamento, após múltiplas administrações de GEH200520 Injection com GEH200521 (18F) Injection para indivíduos da Parte B.
Prazo: 50 dias
|
50 dias
|
|
|
To characterize the pharmacokinetic (PK) properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Prazo: 7 days
|
The PK parameter to be assessed: AUC |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Prazo: 7 days
|
The PK parameter to be assessed: Cmax |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Prazo: 7 days
|
The PK parameter to be assessed: CL |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Prazo: 7 days
|
The PK parameter to be assessed: V |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Prazo: 7 days
|
The PK parameter to be assessed: t1/2 |
7 days
|
|
Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs, for Part A subjects.
Prazo: 7 days
|
Incidence of AEs, SAEs, and Treatment-emergent AEs by system organ class and preferred term |
7 days
|
|
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Prazo: Baseline, 24 hours, 7 days post IMP administration
|
The findings in the physical exam pre and post-administration will be summarized. |
Baseline, 24 hours, 7 days post IMP administration
|
|
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Prazo: Baseline, 24 hours, 7 days post IMP administration
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized. |
Baseline, 24 hours, 7 days post IMP administration
|
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Prazo: Baseline, 24 hours, 7 days post IMP administration
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects. |
Baseline, 24 hours, 7 days post IMP administration
|
|
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Prazo: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration heart rate values outside the normal limits will be summarized. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Prazo: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration blood pressure values outside the normal limits will be summarized. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Prazo: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration body temperature values outside the normal limits will be summarized. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Prazo: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
Descriptive statistics will be used to describe the observed values and change from baseline. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Prazo: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration physical exam status values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Prazo: Baseline, Day 15, Day 36, Day 50
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Prazo: Baseline, Day 15, Day 36, Day 50
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Prazo: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration heart rate values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Prazo: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration blood pressure values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Prazo: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration body temperature values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Prazo: Baseline, Day 15, Day 36, Day 50
|
Descriptive statistics will be used to describe the observed values and change from baseline. |
Baseline, Day 15, Day 36, Day 50
|
|
To characterize the PK properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Prazo: 50 days
|
The PK parameter to be assessed: AUC |
50 days
|
|
To characterize the PK properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Prazo: 50 days
|
The PK parameter to be assessed: Cmax |
50 days
|
|
To characterize the PK properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Prazo: 50 days
|
The PK parameter to be assessed: CL |
50 days
|
|
To characterize the PK properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Prazo: 50 days
|
The PK parameter to be assessed: V |
50 days
|
|
To characterize the PK properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Prazo: 50 days
|
The PK parameter to be assessed: t1/2 |
50 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Ravi Karra, MD, GE Healthcare
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- GE-269-001
- 2024-515218-42-00 (Ctis)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .